NIR‐II Photoacoustic Imaging‐Guided Oxygen Delivery and Controlled Release Improves Photodynamic Therapy for Hepatocellular Carcinoma

Hypoxia, a prominent hallmark of hepatocellular carcinoma (HCC), undermines curative outcomes, elevates recurrence rates, and fosters metastasis, particularly during photodynamic therapy (PDT) in clinical settings. Studies indicate that alleviating tumor hypoxia enhances PDT efficacy. However, persi...

Full description

Saved in:
Bibliographic Details
Published in:Advanced materials (Weinheim) 2024-01, Vol.36 (4), p.e2308780-n/a
Main Authors: Zeng, Silue, Chen, Jingqin, Gao, Rongkang, Chen, Rui, Xue, Qiang, Ren, Yaguang, Liu, Liangjian, Tang, Chuanyu, Hu, Haoyu, Zeng, Ning, Wen, Sai, Zhang, Hai, Liu, Chengbo, Fang, Chihua
Format: Article
Language:English
Subjects:
Biomimetics
Blood
Cancer
Carcinoma, Hepatocellular - diagnostic imaging
Carcinoma, Hepatocellular - drug therapy
Cell Line, Tumor
Cell membranes
Controlled release
Delayed-Action Preparations
Effectiveness
hepatocellular carcinoma
Humans
Hypoxia
Liver cancer
Liver Neoplasms - diagnostic imaging
Liver Neoplasms - drug therapy
Medical imaging
Nanoparticles
Near infrared radiation
Oxygen
oxygen controlled release
photoacoustic imaging
Photoacoustic Techniques
Photochemotherapy - methods
Photodynamic therapy
Photosensitizing Agents - pharmacology
Photosensitizing Agents - therapeutic use
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypoxia, a prominent hallmark of hepatocellular carcinoma (HCC), undermines curative outcomes, elevates recurrence rates, and fosters metastasis, particularly during photodynamic therapy (PDT) in clinical settings. Studies indicate that alleviating tumor hypoxia enhances PDT efficacy. However, persistent challenges, including suboptimal oxygen delivery efficiency and absence of real‐time feedback on blood oxygen fluctuations during PDT, considerably impede therapeutic efficacy in tumor treatment. This study addresses these issues using near‐infrared‐II (NIR‐II) photoacoustic (PA) imaging for tumor‐targeted oxygen delivery and controlled release. For this purpose, a biomimetic oxygen delivery system designated BLICP@O2 is developed, which utilizes hybrid tumor cell membranes and thermosensitive liposomes as oxygen carriers, incorporating the NIR‐II dye IR1048, photosensitizer chlorin e6 (Ce6), and perfluorohexane. Upon sequential irradiation at 1064 and 690 nm, BLICP@O2 exhibits significant photothermal and photodynamic effects. Photothermal heating triggers oxygen release, enhancing the photodynamic effect of Ce6. Blood oxygen changes during PDT are tracked by multispectral PA imaging. Enhanced PDT efficacy, mediated by hypoxia relief, is convincingly demonstrated both in vitro and in vivo. This work presents an imaging‐guided, dual‐wavelength programmed cascaded treatment strategy for tumor‐targeted oxygen delivery and controlled release, with real‐time efficacy monitoring using PA imaging, offering valuable insights for overcoming challenges in PDT‐based cancer therapy. This work develops a new theranostic strategy for photoacoustic (PA)‐guided oxygen delivery, controlled release, and photodynamic therapy (PDT). The strategy demonstrates precise thermal‐triggered oxygen release in situ of tumor, evaluated by real‐time multispectral PA imaging of blood oxygen levels during PDT. This developed strategy, assisted by near‐infrared‐II PA imaging, provides a novel approach for hepatocellular carcinoma treatment and therapeutic monitoring.
ISSN:0935-9648
1521-4095
DOI:10.1002/adma.202308780